PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1
NCT00829829
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
241
Enrollment
INDUSTRY
Sponsor class
Conditions
Intercritical Gout
Interventions
OTHER:
Placebo
DRUG:
Rilonacept 80 mg
DRUG:
Rilonacept 160 mg
Sponsor
Regeneron Pharmaceuticals